Guggenheim reissued their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE - Free Report) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $19.00 price objective on the stock.
MAZE has been the topic of a number of other reports. Leerink Partnrs raised shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price target for the company. Leerink Partners assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price objective on the stock. Finally, TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $25.67.
Read Our Latest Research Report on MAZE
Maze Therapeutics Stock Performance
Shares of NASDAQ MAZE traded down $0.19 during mid-day trading on Wednesday, hitting $8.88. 190,855 shares of the stock traded hands, compared to its average volume of 301,280. Maze Therapeutics has a 52 week low of $8.33 and a 52 week high of $17.00.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($18.32) EPS for the quarter, missing analysts' consensus estimates of ($7.60) by ($10.72).
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
